Oppenheimer Rates MediWound Outperform

Summary

Oppenheimer has started covering MediWound (NASDAQ: MDWD) with an ‘outperform’ rating and set a price target of $34.00, suggesting a potential upside of 54.72%. Other analysts have varied opinions, with one giving a ‘sell’ rating and others ‘buy’ ratings, with price targets ranging from $25.00 to $39.00. The current consensus rating for MediWound is ‘moderate buy’, with a price target of $31.80. The stock recently traded at $21.98, with a market cap of $237.51 million and negative earnings per share of $0.07.Market Beat

Impact Analysis

The event is at the company level since it pertains specifically to MediWound. Oppenheimer’s ‘outperform’ rating and price target of $34.00 could lead to increased investor interest and potential upward movement in the stock price as investors react to the new analyst coverage. The price target implies a significant upside potential of over 54%, which could attract value-seeking investors. The consensus rating of ‘moderate buy’ and a target price of $31.80 offer additional context to the market’s general sentiment towards MediWound, suggesting an overall positive outlook but with some dissenting views. Investors might see this as an opportunity given the stock’s current trading price of $21.98, which is lower than both the Oppenheimer target and the consensus target. However, the negative earnings per share indicate underlying financial challenges that could pose risks.Market Beat